Given that re‐treatment does not preclude subsequent HBsAg loss, we suggest early re‐treatment for individuals who experience a hepatitis flare (ALT > 5× ULN), particularly when accompanied by a HBV DNA level ≥ 4 log10 IU/mL. The gene discussed is GPT; the disease is hepatitis A virus infection.